3/12/2021 6:00:56 AM
Bayer Plans To Further Strengthen Supervisory Board; Supervisory Board Compensation To Be Adjusted
3/10/2021 7:56:24 AM
Bayer Expects Core EPS To Be EUR 7.00-EUR 7.50 In 2024 Based On Constant Currencies
2/25/2021 1:32:19 AM
Bayer Q4 EPS EUR 0.32 Vs EUR 1.44 Last Year
2/8/2021 7:09:34 AM
Bayer, Orion Expand Clinical Development Program For Oral ARi NUBEQA In Prostate Cancer
2/3/2021 5:15:16 PM
Bayer Announces Formal Agreement With Plaintiffs' Class Counsel On Class Plan
2/3/2021 6:34:11 AM
Bayer Receives Approval For Nubeqa In China For Treatment Of Men With NmCRPC
2/1/2021 2:11:24 AM
Bayer Receives Approval For Use Of Its Oral Factor Xa Inhibitor Xarelto
1/13/2021 3:16:00 AM
Bayer Presents Progress In Transforming Its Pharmaceutical Business
12/21/2020 7:54:22 AM
WuXi Biologics To Take Over And Operate Drug Substance Facility At Bayer's Wuppertal Site
12/1/2020 3:12:07 AM
Bayer Announces Placement Of Elanco Shares For Gross Proceeds Of $1.6 Bln At Completion